Related Experiment Videos

Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma

H U Kontny1, T M Lehrnbecher, S J Chanock

  • 1Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Cancer Research
|December 29, 1998
PubMed

Insights

Ewing's sarcoma cells express Fas ligand, but it is not functional. This suggests that Ewing's sarcoma is a potential target for immunotherapy, as the tumor cells are susceptible to immune attack.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Fas-Fas ligand interactions are crucial for immune response regulation.
  • Tumor-expressed Fas ligand can suppress host anti-tumor immunity by eliminating effector lymphocytes.

Purpose of the Study:

  • To investigate the expression and functional status of Fas and Fas ligand in Ewing's sarcoma.
  • To determine if Ewing's sarcoma cells are susceptible to Fas-mediated apoptosis and if their expressed Fas ligand is functional.

Main Methods:

  • Analysis of Fas and Fas ligand expression in Ewing's sarcoma cell lines using immunoblot, reverse transcription-PCR, and flow cytometry.
  • Assessment of Fas-mediated apoptosis induction and effector lymphocyte generation/lysis.
  • Treatment with interferon-gamma (IFN-gamma) and/or cycloheximide.

Main Results:

  • All Ewing's sarcoma cell lines expressed Fas, with some sensitive to Fas-mediated apoptosis.
  • Fas ligand protein was detected in all cell lines, but it was not functional, failing to induce apoptosis in sensitive cells.
  • Ewing's sarcoma cells could stimulate effector lymphocytes and were susceptible to lysis by them.

Conclusions:

  • Fas ligand is expressed but non-functional in Ewing's sarcoma.
  • Ewing's sarcoma exhibits susceptibility to immune-mediated killing, indicating its potential as a target for immunotherapy.

Related Concept Videos